---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Executive summary: Disease burden"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Disease burden. 1 evidence topic quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary/disease-burden"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Chronic inflammatory demyelinating polyneuropathy

<a id="topic-1.1.1-1"></a>

### Summary

In a 2023 US claims analysis, the adjusted prevalence of CIDP was 23.3 per 100,000 persons, corresponding to an estimated 77,058 individuals, and the adjusted incidence was 2.8 per 100,000 persons, or approximately 9,238 patients diagnosed in 2023. Pooled estimates across studies were a prevalence of 2.81 per 100,000 and a crude incidence of 0.33 per 100,000 person-years, and heterogeneity across studies was partly explained by the use of different diagnostic criteria. In one survey, 78% of patients had a progressive or relapsing course and 18% could not walk independently at the last visit; pooled estimates across studies were a remission rate of 40.8% and a case fatality rate of 3.3%.

Health-related quality of life is reduced. In a cross-sectional survey in eight countries including the United States, in which 164 physicians provided data for 1056 participants, the mean EQ-5D-5L score was 0.662, and the authors reported lower HRQoL than in the general population; a review of humanistic burden studies reported that, in one study (n = 76), 17% and 74% of patients reported severe pain and severe fatigue, respectively. In a survey of individuals with self-reported CIDP, 44% of those with likely CIDP stopped working because of their symptoms.

In a US claims case-control analysis, mean total costs over 2 years were $116,330 for 790 cases compared with $15,586 for 790 matched controls, and CIDP therapy accounted for 51.2% of mean total costs among cases. In a second US claims analysis, mean first-year all-cause cost was $105,554 for all patients and $247,456 for chronic immunoglobulin users, who made up 62% of immunoglobulin users.

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/); [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/); [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/); [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/); [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/); [Querol et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8463372/); [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/); [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/); [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
